WCA
ONCT

Waypoint Capital Advisors’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Waypoint Capital Advisors’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,314
Closed -$7.88K – 121
2023
Q3 		$7.88K Sell
1,314
-599
-31% -$4.22K ﹤0.01% 115
2023
Q2 		$13.4K Hold
1,913
– – ﹤0.01% 132
2023
Q1 		$30K Hold
1,913
– – 0.01% 133
2022
Q4 		$38.3K Buy
+1,913
New +$38.1K 0.01% 128
2022
Q2 		– Sell
-2,219
Closed -$52K – 143
2022
Q1 		$52K Buy
+2,219
New +$80.8K 0.03% 116

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PPW
Pasadena Private Wealth Pasadena, California $723M AUM 18.72% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return

Waypoint Capital Advisors's ONCT Position: Q4 2023 in Review

Waypoint Capital Advisors sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2023, closing a stake of 1,314 shares — an estimated $7.88K sold.

Waypoint Capital Advisors first reported a position in ONCT in Q1 2022 and held it in 5 quarters. The position peaked at $52K in Q1 2022. 38 funds tracked by Wall St. Rank hold ONCT as of Q4 2023.

  • Waypoint Capital Advisors reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Waypoint Capital Advisors sold 1,314 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $7.88K.
  • Waypoint Capital Advisors first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
  • Waypoint Capital Advisors's Oncternal Therapeutics, Inc. Common Stock position peaked at $52K in Q1 2022.
  • 38 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Waypoint Capital Advisors's 13F filing for Q4 2023, filed 22 Jan 2024.